Prof Wiedermann - January presentation in SF, page-80

If the early trial data is good then i expect imugene to be bought out a lot sooner.
It would not surprise me if a chinese pharmaceutical company makes a move on imugene.
Watching paul hoopers most recent interview he stated the chinese are acquiring american biotechs
The have a population of 1.3 billion people and a huge cancer market.
The chinese purchased 30 million shares in viralytics before Merck bought out viralytics.
That would certainly upset the apple cart. Roche,merck and bristol squire squibb want imugene.
Which ever pharmaceutical company moves first on imugene then they get the exclusive rights to its B cell vaccine technology.